About Collaboration with AbbVie
In October 2017, Alector entered into a global strategic partnership with AbbVie (NYSE:ABBV) a global, research-driven biopharmaceutical company, to develop and commercialize medicines to treat Alzheimer’s disease and other neurodegenerative disorders. Under the terms of the agreement, AbbVie has an option for the global development and commercial rights to two targets, including TREM2. Alector will conduct exploratory research, drug discovery and development for lead programs up to the conclusion of the proof-of-concept (PoC) studies. Upon exercise of the option, AbbVie will lead development and commercialization activities. Alector and AbbVie will co-fund development and commercialization and will share global profits equally.